Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 randomized, controlled clinical trial of AB-SA01 in patients with S. aureus bacteremia

Trial Profile

A Phase 1/2 randomized, controlled clinical trial of AB-SA01 in patients with S. aureus bacteremia

Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs AB SA01 (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Nov 2018 According to an AmpliPhi Biosciences Corporation media release, the company intends to initiate this trial in 2019.
    • 27 Sep 2018 New trial record
    • 17 Sep 2018 According to an AmpliPhi Biosciences Corporation media release, FDA is in general agreement with the design of proposed this clinical trial and no additional preclinical or clinical data are required to proceed with both trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top